Spain

Publication

How Have HTA Agencies Evolved Their Methods Over Time?

29 April 2024

The many changes in Health Technology Assessment (HTA) methods and processes over time, are a challenge to navigate let alone stay abreast of. This report explores the breadth of variation in past and current positioning of HTA agencies in 14 countries, on five key methodological topics: discount rates, modifiers, patient involvement, real-world evidence (RWE), and surrogate endpoints.

Are Recommendations for HTA of Gene Therapies Being Achieved?
Publication

Are Recommendations for HTA of Gene Therapies Being Achieved?

11 September 2023

In this report, commissioned and funded by Pfizer, we explore the extent to which previous OHE recommendations for the health technology assessment (HTA) of gene therapies are being achieved in nine European countries, Australia, and Canada.

Spain
Insights

Around The World in HTAs: Spain – Are We There Yet?

15 March 2023

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.

Insights

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

24 February 2021

This blog summarises an initiative taken by more than 300 health economists and experts in support of the creation of an independent health technology assessment agency…

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies
Publication

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

8 January 2020

Histology independent therapies, a new class of medicines that target cancer based on specific genomic or molecular alterations of cancer cells rather than tissue of origin,…

AZ Report Cover Page
Publication

The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries

5 January 2018

The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally…

Publication

Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries

1 November 2009

This study compares pricing and reimbursement (P&R) policy for 43 orphan medicinal products (OMPs) across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden…